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ABSTRACT
Objectives To investigate efficacy and safety of the Janus 
kinase-1 inhibitor filgotinib in patients with active rheumatoid 
arthritis (RA) with limited or no prior methotrexate (MTX) 
exposure.
Methods This 52- week, phase 3, multicentre, double- 
blind clinical trial (NCT02886728) evaluated once- daily 
oral filgotinib in 1252 patients with RA randomised 2:1:1:2 
to filgotinib 200 mg with MTX (FIL200 +MTX), filgotinib 
100 mg with MTX (FIL100 +MTX), filgotinib 200 mg 
monotherapy (FIL200), or MTX. The primary endpoint was 
proportion achieving 20% improvement in American College 
of Rheumatology criteria (ACR20) at week 24.
Results The primary endpoint was achieved by 81% of 
patients receiving FIL200+ MTX versus 71% receiving 
MTX (p<0.001). A significantly greater proportion treated 
with FIL100+ MTX compared with MTX achieved an 
ACR20 response (80%, p=0.017) at week 24. Significant 
improvement in Health Assessment Questionnaire- Disability 
Index was seen at week 24; least- squares mean change 
from baseline was −1.0 and −0.94 with FIL200+MTX and 
FIL100+MTX, respectively, versus −0.81 with MTX (p<0.001, 
p=0.008, respectively). Significantly higher proportions 
receiving FIL200+MTX (54%) and FIL100+MTX (43%) 
achieved DAS28(CRP) <2.6 versus MTX (29%) (p<0.001 for 
both) at week 24. Hierarchical testing stopped for comparison 
of ACR20 for FIL200 monotherapy (78%) versus MTX (71%) 
at week 24 (p=0.058). Adverse event rates through week 52 
were comparable between all treatments.
Conclusions FIL200+MTX and FIL100+MTX both 
significantly improved signs and symptoms and physical 
function in patients with active RA and limited or no prior 
MTX exposure; FIL200 monotherapy did not have a superior 
ACR20 response rate versus MTX. Filgotinib was well 
tolerated, with acceptable safety compared with MTX.
INTRODUCTION
Early control of rheumatoid arthritis (RA), 
including initiation of effective treatment as 
soon as possible, is critical to prevent disability, 
joint destruction, and decreased quality of life 
(QoL).1–4 For patients, the highest priority is 
returning to normality quickly.5 The European 
Key messages
What is already known about this subject?
 ► Results from previous phase 3 studies and 
subsequent long- term follow- up of baricitinib, 
upadacitinib, and tofacitinib showed that 
treatment with small molecule Janus kinase 
(JAK) inhibitors with or without conventional 
synthetic disease- modifying antirheumatic 
drugs have a clinically meaningful benefit over 
methotrexate (MTX) monotherapy in reducing 
the signs and symptoms of rheumatoid arthritis, 
as well as radiographic progression, in MTX- 
naïve patients.
 ► Safety signals such as increased risk of 
infections, venous thromboembolism, and 
major adverse cardiovascular event warrant 
careful evaluation of the risks and benefits of 
treatment, especially in the first- line treatment.
What does this study add?
 ► This study is the first to evaluate filgotinib—a 
once- daily, oral, selective JAK-1 inhibitor—in 
patients with rheumatoid arthritis who had no 
or limited exposure to MTX.
 ► Filgotinib, either alone or in combination with 
MTX, was found to have a clinically meaningful 
benefit over MTX monotherapy with an 
acceptable safety profile up to 52 weeks.
How might this impact on clinical practice or 
future developments?
 ► Filgotinib in combination with MTX could be 
considered as a treatment option for patients 
with moderately or severely active rheumatoid 
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Table 1 Baseline demographics and clinical characteristics
  FIL 200 mg+MTX n=416 FIL 100 mg+MTX n=207 FIL 200 mg n=210 MTX n=416
Total
N=1249
Age, years 53 (13.8) 54 (12.6) 52 (13.9) 53 (13.7) 53 (13.6)
  ≥65 years, n (%) 87 (21) 39 (19) 40 (19) 87 (21) 253 (20)
  ≥70 years, n (%) 42 (10) 18 (9) 22 (11) 44 (11) 126 (10)
  ≥75 years, n (%) 21 (5) 7 (3) 10 (5) 16 (4) 54 (4)
Female, n (%) 325 (78%) 158 (76%) 166 (79%) 312 (75%) 961 (77%)
Race, n (%)
  White 278 (67%) 132 (64%) 135 (64%) 278 (67%) 823 (66%)
  Asian 90 (22%) 51 (25%) 47 (22%) 85 (20%) 273 (22%)
  American Indian or Alaska Native 26 (6%) 12 (6%) 18 (9%) 33 (8%) 89 (7%)
  Black or African American 15 (4%) 8 (4%) 8 (4%) 14 (3%) 45 (4%)
  Native Hawaiian or Pacific Islander 1 (<1%) 0 1 (1%) 3 (1%) 5 (<1%)
  Other* 6 (1%) 4 (2%) 0 3 (1%) 13 (1%)
  Not permitted* 0 0 1 (1%) 0 1 (<1%)
Ethnicity, n (%)
  Hispanic or Latino 93 (22%) 40 (19%) 45 (21%) 84 (20%) 262 (21%)
  Not Hispanic or Latino 322 (77%) 167 (81%) 165 (79%) 332 (80%) 986 (79%)
  Not permitted* 1 (<1%) 0 0 0 1 (<1%)
Geographical region,† n (%)
  Region A 173 (42%) 85 (41%) 86 (41%) 170 (41%) 514 (41%)
  Region B 149 (36%) 75 (36%) 76 (36%) 149 (36%) 449 (36%)
  Region C 58 (14%) 28 (14%) 28 (13%) 56 (14%) 170 (14%)
  Region D 13 (3%) 8 (4%) 8 (4%) 16 (4%) 45 (4%)
  Region E 23 (6%) 11 (5%) 12 (6%) 25 (6%) 71 (6%)
BMI, median (Q1, Q3), kg/m2 26.8 (23.0, 31.2) 26.7 (23.5, 31.3) 26.4 (23.3, 30.0) 26.8 (23.1, 31.5) 26.7 (23.1, 31.1)
Smoking status, n (%)
  Non- smoker 300 (72%) 146 (71%) 151 (72%) 287 (69%) 884 (71%)
  Former smoker 64 (15%) 32 (16%) 24 (11%) 70 (17%) 190 (15%)
  Current smoker 52 (13%) 29 (14%) 35 (17%) 59 (14%) 175 (14%)
RA duration, years 1.9 (3.6) 2.3 (4.7) 2.6 (6.3) 2.3 (5.5) 2.2 (5.0)
  Median 0.4 0.4 0.4 0.3 0.4
  ≤6 month 229 (55%) 111 (54%) 116 (55%) 230 (55%) 686 (55%)
  6 month–1 year 40 (10%) 27 (13%) 21 (10%) 52 (13%) 140 (11%)
  ≥1 year 147 (35%) 69 (33%) 73 (35%) 134 (32%) 423 (34%)
RF or anti- CCP positive, n (%) 317 (76%) 162 (78%) 158 (75%) 322 (77%) 959 (77%)
hsCRP (mg/L) 18.0 (25.3) 17.7 (27.4) 17.3 (23.2) 16.9 (24.4) 17.5 (25.0)
mTSS erosions>0, n (%) 392 (94%) 197 (95%) 199 (95%) 385 (93%) 1173 (94%)
DMARD naïve, n (%) 319 (77%) 159 (77%) 164 (78%) 322 (77%) 964 (77%)
Prior non- MTX csDMARD use, n (%) 73 (18%) 38 (18%) 35 (17%) 76 (18%) 222 (18%)
Concurrent antimalarial use, n (%) 35 (8%) 24 (12%) 17 (8%) 42 (10%) 118 (9%)
Concurrent oral steroid use, n (%) 143 (34%) 88 (43%) 89 (42%) 174 (42%) 494 (40%)
Steroid dose, mg/day 6.6 (2.3) 7.2 (2.9) 6.6 (2.2) 6.5 (2.3) 6.6 (2.4)
DAS28(CRP) 5.7 (1.0) 5.7 (1.0) 5.8 (0.9) 5.7 (1.0) 5.7 (1.0)
SJC66 16 (9.8) 16 (9.3) 16 (9.7) 16 (9.4) 16 (9.6)
TJC68 26 (14.5) 25 (13.9) 26 (13.7) 26 (13.8) 26 (14.0)
Patient global assessment (VAS) 65 (21.0) 66 (21.6) 68 (19.2) 66 (21.0) 66 (20.8)
Physician global assessment (VAS) 66 (17.0) 68 (6.3) 66 (14.4) 67 (16.8) 67 (16.4)
Patient pain (VAS) 64 (22.0) 67 (22.1) 67 (18.4) 66 (21.4) 65 (21.3)
HAQ- DI 1.5 (0.6)‡ 1.6 (0.7) 1.6 (0.7) 1.6 (0.6) 1.6 (0.6)
mTSS units§ 11.4 (20.0) 13.3 (27.0) 16.5 (32.4) 13.7 (29.2) 13.3 (26.7)
CDAI 39.5 (12.8) 39.2 (12.7) 40.0 (12.6) 40.2 (12.5) 39.8 (12.6)
SDAI 41.3 (13.4) 41.0 (13.5) 41.8 (13.1) 41.9 (13.4) 41.5 (13.4)
SF-36 PCS 33.9 (7.5)‡ 33.7 (8.0) 33.6 (7.7)¶ 33.3 (7.3) 33.6 (7.5)
FACIT- F 28.3 (10.9)** 27.3 (11.9) 27.3 (10.9)†† 27.1 (10.7)‡‡ 27.6 (11.0)
Data are mean (SD), unless otherwise indicated.
*Other races included people whose predominant origins cannot be determined or who are of mixed race and do not identify with a primary race. Not permitted category includes patients whose local regulators did not allow collection of race or 
ethnicity information.
†Region A: USA, Spain, Germany, South Korea, Canada, Belgium, South Africa, Australia, New Zealand, UK, Italy, Ireland, Israel; Region B: India, Poland, Ukraine, Bulgaria, Russia, Czech Republic, Hungary, Serbia, Romania, Slovakia; Region C: 







BMI, body mass index; CCP, cyclic citrullinated peptides; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic DMARD; DAS28(CRP), 28- joint Disease Activity Score with C- reactive protein; DMARD, disease- modifying 
antirheumatic drug; FACIT- F, Functional Assessment of Chronic Illness Therapy–Fatigue; FIL, filgotinib; HAQ- DI, Health Assessment Questionnaire–Disability Index; hsCRP, high- sensitivity C- reactive protein; mTSS, Modified total Sharp/van der Heijde 
score; MTX, methotrexate; SF-36 PCS, Short Form 36 Physical Component Summary score; Q1, first quartile; Q3, third quartile; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index; SJC66, swollen joint count based 
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League Against Rheumatism (EULAR) and American College 
of Rheumatology (ACR) recommend initial therapy with 
methotrexate (MTX) alone or with glucocorticoids to 
induce remission or low disease activity by week 24, pref-
erentially maintained over time.2 6 However, only approxi-
mately 30% of patients with RA achieve this objective with 
MTX monotherapy.7 8 Following treat to target approaches, 
including temporary glucocorticoids, this might increase 
to 60%–70%.9 Thus, alternative therapies providing rapid 
disease control are desirable. Such therapies will also benefit 
patients with seropositivity, elevated acute phase reactants, 
and early erosions, which, in a recently updated matrix, 
predict rapid radiographic progression.10
Filgotinib, an oral, selective Janus kinase (JAK)-1 inhib-
itor, was efficacious in phase 2 and phase 3 trials in patients 
with RA.11–14 In these trials, filgotinib 200 or 100 mg daily 
with conventional synthetic disease- modifying antirheu-
matic drugs (DMARDs) or as monotherapy demonstrated 
rapid, significant improvements in disease activity versus 
placebo.11–14 This phase 3 study (NCT02886728) evalu-
ated the efficacy and safety of filgotinib with MTX or as 
monotherapy as compared with standard of care MTX 
monotherapy in patients with active RA with limited or no 
prior MTX exposure.
METHODS
Study design and conduct
This 52- week, randomised, double- blind, active- controlled, 
phase 3 trial was conducted at 227 sites in 31 countries from 
8 August 2016 to 5 October 2018. Patients were randomised 
2:1:1:2 to receive filgotinib 200 mg with MTX (FIL200+MTX), 
filgotinib 100 with MTX (FIL100+MTX), filgotinib 200 mg 
(FIL200), or MTX. Patients provided written informed consent 
prior to screening.
Study participants
Eligible patients were ≥18 years with RA per 2010 ACR/EULAR 
criteria,15 limited (<3 doses ≤25 mg) or no prior MTX expo-
sure, ≥6 swollen joint count of 66 joints (SJC66)), and ≥6 tender 
joints of 68 joints (TJC68)) at screening and day 1. At screening, 
eligible patients were required to have 1 of the following: sero-
positivity for rheumatoid factor and/or anticyclic citrullinated 
peptide or ≥1 radiographic erosion (centrally read); or serum 









FIL 100 mg QD + MTX QW
n=207
FIL 200 mg QD 
n=210
Completed 




Study drug discontinued 
between weeks 0–24
n=40 (9.6%)
• Subject decision 14 (3.4%)
• Adverse event 17 (4.1%)
• Lost to follow-up 6 (1.4%)
• Lack of efficacy 0
• Investigator’s discretion 1 
(0.2%)
• Noncompliance with study 
drug 1 (0.2%)
• Death 1 (0.2%)
• Pregnancy 0
Completed 




Study drug discontinued 
between weeks 0–24
n=43 (10.3%)
• Subject decision 20 (4.8%)
• Adverse event 5 (1.2%)
• Lost to follow-up 8 (1.9%)
• Lack of efficacy 7 (1.7%)
• Investigator’s discretion 3 
(0.7%)









Study drug discontinued 
between weeks 0–24
n=14 (6.8%)
• Subject decision 7 (3.4%)
• Adverse event 5 (2.4%)
• Lost to follow-up 1 (0.5%)
• Lack of efficacy 1 (0.5%)
• Investigator’s discretion 0









Study drug discontinued 
between weeks 0–24
n=22 (10.5%)
• Subject decision 6 (2.9%)
• Adverse event 4 (1.9%)
• Lost to follow-up 7 (3.3%)
• Lack of efficacy 2 (1.0%)
• Investigator’s discretion 1 
(0.5%)
• Noncompliance with study 
drug 1 (0.5%)
• Death 0
• Pregnancy 1 (0.5%)








Study drug discontinued 
between weeks 0–52
n=83 (20.0%)
• Adverse event 29 (7.0%)
• Subject decision 20 (4.8%)
• Lack of efficacy 13 (3.1%)
• Lost to follow-up 10 (2.4%)
• Investigator’s discretion 4 
(1.0%)
• Protocol violation 2 (0.5%)
• Death 3 (0.7%)








Study drug discontinued 
between weeks 0–52
n=116 (27.9%)
• Adverse event 25 (6.0%)
• Subject decision 32 (7.7%)
• Lack of efficacy 34 (8.2%)
• Lost to follow-up 11 (2.6%)
• Investigator’s discretion 6 
(1.4%)
• Protocol violation 8 (1.9%)
• Death 0








Study drug discontinued 
between weeks 0–52
n=35 (16.9%)
• Adverse event 13 (6.3%)
• Subject decision 10 (4.8%)
• Lack of efficacy 7 (3.4%)
• Lost to follow-up 4 (1.9%)
• Investigator’s discretion 1 
(0.5%)
• Protocol violation 0
• Death 0








Study drug discontinued 
between weeks 0–52
n=40 (19.0%)
• Adverse event 5 (2.4%)
• Subject decision 9 (4.3%)
• Lack of efficacy 9 (4.3%)
• Lost to follow-up 11 (5.2%)
• Investigator’s discretion 2 
(1.0%)
• Protocol violation 2 (1.0%)
• Death 0
• Noncompliance with study 
drug 1 (0.5%)
• Pregnancy 1 (0.5%)
Figure 1 Study flow and patient disposition through 24 and 52 weeks. *Three patients were randomised (1 to FIL 200 mg+MTX and 2 to MTX 
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included previous use of JAK inhibitors or biological DMARDs. 
Prior or concomitant use of stably dosed hydroxychloroquine 
was allowed. Full inclusion/exclusion criteria are in online 
supplemental methods.
Interventions
Filgotinib 100 or 200 mg were administered orally once daily. 
MTX was administered orally once weekly, starting with 10 mg/
week and escalating to 15 mg at week 4 and 20 mg at week 
8; in Japan, maximum 15 mg/week per local MTX prescribing 
practices. Local standard of care for folic acid supplementation 
was followed. After 4 weeks, a one- time 5 mg MTX dose reduc-
tion for intolerance was permitted if the dose remained ≥10 mg. 
Concomitant stable doses of non- steroidal anti- inflammatory 
drugs or glucocorticoids (≤10 mg/d prednisone/equivalent) 
were permitted.
Patients without 20% improvement from baseline in SJC66 
and TJC68 at week 24, or at 2 consecutive visits from weeks 
30 through 52, discontinued study drug and received standard 
of care, but continued study visits. Eligible patients completing 
the study could enter the long- term extension study (LTE) 
(NCT03025308); all others had a 4- week post- treatment visit.
Endpoints
The primary endpoint was proportion of patients receiving 
FIL200+MTX versus MTX achieving ACR2016 at week 24. 
Key secondary endpoints tested hierarchically at week 24 were 
ACR20 FIL100+MTX versus MTX, change from baseline in 
Health Assessment Questionnaire- Disability Index (HAQ- DI), 
proportion of patients achieving 28- joint Disease Activity Score 
(DAS28(CRP))<2.6, change from baseline in modified total 
Sharp/van der Heijde score (mTSS), Short Form 36–Physical 
Component Score (SF-36 PCS), and Functional Assessment of 
Chronic Illness Therapy- Fatigue (FACIT- F; online supplemental 
figure S1).
Additional secondary and other endpoints evaluated over 52 
weeks were the proportion of patients achieving ACR20/50/70, 
DAS28(CRP) <2.6, Simplified Disease Activity Index 
(SDAI)≤3.3, Clinical Disease Activity Index (CDAI) ≤2.8, and 
Boolean remission; and change from baseline in mTSS and its 
components, individual ACR components, DAS28(CRP), CDAI 
and SDAI. Radiographs were scored centrally as campaign A 
(radiographs taken at baseline and week 24) and campaign B 
(radiographs taken at baseline, week 24, and week 52 for patients 
who had images after week 24) by 2 blinded assessors and adju-
dicated by a third assessor, if necessary. Additional details are in 
online supplemental methods.
Safety was evaluated through adverse events (AEs) and labo-
ratory assessments. All potential major adverse cardiovascular 
events (MACE) and thromboembolic events were adjudicated 
centrally by an independent committee. An independent data 
monitoring committee reviewed safety data periodically.
Figure 2 Primary, key secondary, and other secondary efficacy outcomes: (A) proportion of patients who achieved ACR20 over time; (B) change 
from baseline in HAQ- DI at week 24 and week 52; (C) proportion of patients achieving DAS28(CRP) <2.6 at week 24 and week 52. ###p<0.001; 
##p<0.01; #p<0.05. The difference between filgotinib 200 mg and MTX for ACR20 at week 24 was not significant (p=0.058). ***Exploratory 
p<0.001; **exploratory p<0.01; *exploratory p<0.05, for supportive analysis without adjustment for multiplicity. an=372, 190, 185, and 370 for 
FIL200+MTX, FIL100+MTX, FIL200, and MTX, respectively. bn=332, 169, 171, and 307 for FIL200+MTX, FIL100+MTX, FIL200, and MTX, respectively. 
Error bars represent 95% CI for proportions of patients and SD for mean. For HAQ- DI, p values are based on least- squares mean difference versus 
MTX. Supporting values for (A) are shown in online supplemental table S3. ACR20, 20% improvement in American College of Rheumatology criteria; 
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Table 2 Primary and key secondary efficacy outcomes at week 24
  FIL MTX Difference versus MTX* P value versus MTX
Primary outcome
ACR20, FIL200+MTX versus MTX
  n/N 337/416 297/416
  % (95% CI) 81.0 (77.1 to 84.9) 71.4 (66.9 to 75.9) 9.6 (3.6 to 15.6) <0.001†
Key secondary outcomes, hierarchically tested
ACR20, FIL100+MTX versus MTX
  n/N 166/207 297/416
  % (95% CI) 80.2 (74.5 to 85.9) 71.4 (66.9 to 75.9) 8.8 (1.5 to 16.1) 0.017†
HAQ- DI change from baseline, FIL200+MTX versus MTX
  N 372 370
  Mean±SD −0.94±0.72 −0.79±0.63 −0.2 (−0.3, –0.1) <0.001†
HAQ- DI change from baseline, FIL100+MTX versus MTX
  N 190 370
  Mean±SD −0.90±0.68 −0.79±0.63 −0.1 (−0.2, 0.0) 0.008†
DAS28(CRP) <2.6, FIL200+MTX versus MTX
  n/N 225/416 121/416
  % (95% CI) 54.1 (49.2 to 59.0) 29.1 (24.6 to 33.6) 25.0 (18.3 to 31.7) <0.001†
DAS28(CRP) <2.6, FIL100+MTX versus MTX
  n/N 88/207 121/416
  % (95% CI) 42.5 (35.5 to 49.5) 29.1 (24.6 to 33.6) 13.4 (5.0 to 21.8) <0.001†
ACR20, FIL200 versus MTX
  n/N 164/210 297/416
  % (95% CI) 78.1 (72.3 to 83.9) 71.4 (66.9 to 75.9) 6.7 (−0.7 to 14.1) 0.058†
Key secondary outcomes after break in statistical testing hierarchy
HAQ- DI change from baseline, FIL200 versus MTX.
  N 185 370
  Mean±SD −0.89±0.63 −0.79±0.63 −0.1 (−0.2, 0.0) 0.029
DAS28(CRP) <2.6, week 24, FIL200 versus MTX
  n/N 89/210 121/416
  % (95% CI) 42.4 (35.5 to 49.3) 29.1 (24.6 to 33.6) 13.3 (5.0 to 21.6) <0.001
mTSS change from baseline, FIL200+MTX versus MTX
  N 355 356
  LSM (95% CI) 0.1 (−0.2 to 0.4) 0.4 (0.1 to 0.7) −0.3 (−0.6 to 0.0) 0.068
mTSS change from baseline, FIL100+MTX versus MTX
  N 184 356
  LSM (95% CI) 0.1 (−0.2 to 0.5) 0.4 (0.1 to 0.7) −0.3 (−0.7 to 0.1) 0.14
mTSS change from baseline, FIL200 versus MTX
  N 173 356
  LSM (95% CI) −0.1 (−0.5 to 0.2) 0.4 (0.1 to 0.7) −0.6 (−0.9, 0.2) 0.006
SF-36 PCS change from baseline, FIL200+MTX versus MTX
  N 373 371
  Mean±SD 12.3±8.9 9.7±8.6 2.9 (1.8, 4.0) <0.001
SF-36 PCS change from baseline, FIL100+MTX versus MTX
  N 190 371
  Mean±SD 11.1±9.0 9.7±8.6 1.6 (0.3, 2.9) 0.019
SF-36 PCS change from baseline, FIL200 versus MTX
  N 185 371
  Mean±SD 10.4±9.1 9.7±8.6 0.8 (−0.5, 2.2) 0.23
FACIT- F change from baseline, FIL200+MTX versus MTX
  N 365 365
  Mean±SD 10.6±11.5 10.1±11.2 1.3 (−0.1, 2.6) 0.061
FACIT- F change from baseline, FIL100+MTX versus MTX
  N 189 365
  Mean±SD 11.4±11.3 10.1±11.2 1.3 (−0.3, 2.9) 0.11
FACIT- F change from baseline, FIL200 versus MTX
  N 181 365
  Mean±SD 10.2±11.4 10.1±11.2 0.3 (−1.3, 1.9) 0.70
*Difference versus MTX (95% CI) for dichotomous outcomes and LSM difference versus MTX (95% CI) for continuous outcomes.
†P value adjusted for multiplicity. All other p values are exploratory.
ACR20, 20% improvement in American College of Rheumatology criteria; DAS28(CRP), Disease Activity Score in 28 joints with C- reactive protein; FACIT- F, Functional Assessment of Chronic Illness Therapy- Fatigue; 
FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; HAQ- DI, Health Assessment Questionnaire- Disability Index; LSM, least- squares mean; mTSS, Modified total Sharp/van der Heijde score; MTX, methotrexate; SF-36 PCS, 
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Statistical analysis
A sample size of 400 patients receiving FIL200+MTX and 
400 receiving MTX monotherapy would provide 90% power 
at a two- sided α of 0.05 to test superiority of FIL200+MTX 
compared with MTX for change from baseline in mTSS at 
week 24, which is common in RA studies assessing structural 
damage.17–19 The total sample size was 1200 patients (400 
patients for FIL200+MTX group, 200 patients for FIL100 
+MTX group, 200 patients for FIL200 group, and 400 patients 
for MTX group). This sample size also provided >90% power 
to detect a 16% difference in ACR20 between patients receiving 
MTX (estimated response rate, 62%) versus any filgotinib treat-
ment (78%) at a two- sided α of 0.05.
Type I error was controlled by hierarchical testing of primary 
and key secondary endpoints (online supplemental figure S1). 
The primary efficacy hypothesis was a superiority test (two- sided 
α=0.05) comparing ACR20 at week 24 for FIL200 +MTX 
versus MTX, using logistic regression analysis with treatment 
group and stratification factors, and non- responder imputation 
for missing data. Sequential testing for the primary and key 
secondary endpoints was implemented, and when a null hypoth-
esis was not rejected, statistical significance was not considered 
for remaining hypotheses.
Efficacy and safety analyses were based on all randomised 
patients who received ≥1 dose of study drug. Efficacy analyses 
were based on on- treatment data. For binary endpoints, logistic 
regression was used with treatment and stratification factors 
(geographical region and seropositivity at screening) included in 
the model and non- responder imputation. Following treatment 
discontinuation, patient data were imputed as non- responses. 
Treatment effect on continuous endpoint change from baseline 
was evaluated with a mixed- effect model for repeated measures 
with treatment, visit, treatment by visit interaction, stratifica-
tion factors, and baseline value as fixed effects and patient as 
a random effect. For structural endpoints, a linear mixed- effect 
model for change from baseline at week 24 (campaign A) and 52 
(campaign A and B) and a generalised linear mixed- effect model 
for the proportion of patients with no radiographic progression 
(ie, Δ mTSS ≤0) at week 52 using campaign A and B data were 
employed.
Safety endpoints were analysed per treatment by number 
and percentage of patients with events for categorical values or 
summary statistics for continuous data. All statistical analyses 
were performed using SAS V.9.4 (SAS Institute).
Public involvement statement
The public was not involved in the design, conduct, or reporting 
of this research.
Figure 3 Change in modified total Sharp/van der Heijde score (mTSS) and components from baseline at (A) week 24 and (B) week 52. 
***Exploratory p<0.001; **exploratory p<0.01; *exploratory p<0.05; for supportive analysis without adjustment for multiplicity. Error bars represent 
95% CI. For mTSS, week 24 includes only data from campaign A and week 52 includes data from campaign A and B. Week 52 n values are not 
provided for mTSS change from baseline, as the analysis included both campaign A (through week 24) and campaign B (through week 52 including 
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Overall, 1252 patients were randomised, and 1249 received 
study treatment. In total, 90.5% patients completed study drug 
through week 24, and 82% through week 52 (figure 1). The 
largest proportion of patients enrolled from the USA (25.5%) 
and Eastern Europe (26.7%). Baseline demographic and disease 
characteristics were similar among treatment arms (table 1). At 
baseline, median disease duration was 0.4 years, and 77.2% of 
patients were DMARD naïve.
Efficacy
At week 24, the mean dose of MTX was 18 mg/week (online 
supplemental table S1). Significantly higher proportions 
of patients receiving FIL200+MTX (81%, p<0.001) and 
FIL100+MTX achieved ACR20 (80%, p=0.017) versus 
MTX (71%) at week 24 (figure 2A). Patients receiving either 
FIL200+MTX or FIL100+MTX had significant improvement 
in physical function HAQ- DI versus MTX at week 24; the 
least- squares mean (LSM) of the treatment difference in change 
in HAQ- DI from baseline versus MTX (95% CI) was −0.20 
(−0.27,–0.12) (p<0.001) and −0.13 (−0.23,–0.03) (p=0.008) 
for FIL200+MTX and FIL100+MTX, respectively (figure 2B; 
table 2). Significantly higher proportions of patients receiving 
FIL200+MTX and FIL100+MTX achieved DAS28 (CRP) 
<2.6 versus MTX at week 24 (p<0.001 for all comparisons; 
figure 2C; table 2).
ACR20 for FIL200 (78%) at week 24 did not significantly 
differ from MTX (71%; p=0.058) (figure 2A). Therefore, 
exploratory p values without multiplicity adjustment are 
reported for all subsequent endpoints. At week 24, the LSM of 
the treatment difference in change in HAQ- DI from baseline for 
FIL200 versus MTX was −0.11 (figure 2B); 42% of patients 
receiving FIL200 achieved DAS28(CRP) <2.6 versus 29% with 
MTX.
At week 24, the LSM change from baseline in mTSS was 0.13 
with FIL200+MTX, 0.13 with FIL100+MTX, and −0.13 with 
FIL200 versus 0.42 with MTX (figure 3A). Treatment with filgo-
tinib or MTX improved health- related QoL, as measured with 
SF-36 PCS and FACIT- F. At week 24, change from baseline in 
SF-36 PCS was greater for FIL200+MTX and FIL100 +MTX 
versus MTX; and similar to MTX for FIL200, and improvements 
in FACIT- F scores were comparable across treatments (table 2).
At week 52, the LSM change from baseline in mTSS was 0.21 
for FIL200+MTX, 0.27 for FIL100+MTX, and 0.23 for FIL200 
versus 0.74 for MTX (figure 3B). More patients receiving any 
filgotinib treatment had no radiographic progression defined as 
Δ mTSS ≤0 at week 24 versus MTX (online supplemental table 
S2). The cumulative distribution plots of change from baseline in 
mTSS are shown in online supplemental figure S2.
At week 2, ACR20 response was achieved by 42.1%, 37.2%, 
and 39.5% of patients receiving FIL200+MTX, FIL100+MTX, 
and FIL200 versus 16.6% of patients receiving MTX (figure 2A). 
Proportions of patients who achieved ACR50/70 and DAS28 
(CRP) <2.6 or remission at weeks 24 and 52 were higher with 
both doses of FIL+MTX or FIL200 mg versus MTX (figure 4). 
At week 24, all filgotinib groups resulted in greater improvement 
across components of ACR versus MTX (table 3).
Safety
The most common treatment- emergent AEs (TEAEs) occur-
ring in >5% of patients were nausea, upper respiratory tract 
infection, nasopharyngitis, headache and hypertension. Serious 
TEAEs were reported for 6%, 6%, 8%, and 7% of patients 
receiving FIL200+MTX, FIL100+MTX, FIL200, and MTX, 
respectively.
Figure 4 Proportion of patients achieving (A) ACR50 at weeks 24 and 52; (B) ACR70 at weeks 24 and 52; (C) remission at week 24; and (D) 
remission at week 52. ***Exploratory p<0.001; **exploratory p<0.01; *exploratory p<0.05; for supportive analysis without adjustment for 
multiplicity. ACR50/70, 50%/70% improvement in American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; FIL, filgotinib; 
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Over 52 weeks, infection and serious infection rates were 
comparable for filgotinib versus MTX. Infections were 
reported for 36%, 37%, 36%, and 38% of patients receiving 
FIL200+MTX, FIL100+MTX, FIL200, and MTX, respec-
tively; 1%, 1%, 2%, and 2% receiving FIL200+MTX, 
FIL100+MTX, FIL200, and MTX reported serious infections 
(table 4). The most common infections were upper respiratory 
tract infection, nasopharyngitis, urinary tract infection, and 
bronchitis. The most common serious infections were pneu-
monia, bronchitis, and sepsis. There were three opportunistic 
infections (FIL200+MTX, oesophageal candidiasis; MTX, 
Pneumocystis jirovecii pneumonia, pneumonia cryptococcal). 
There was one serious AE of non- disseminated herpes zoster in 
a Japanese patient in their 50s receiving FIL200 who required 
hospitalisation for intravenous antiviral therapy; other cases 
were uncomplicated.
Four deaths occurred: 3 in FIL200+MTX, 1 in FIL100+MTX. 
The causes of death included lupus myocarditis (possible over-
lapping systemic autoimmune disease), intracranial aneurysm, 
interstitial lung disease, and sudden cardiovascular death, which 
occurred 68 days after study drug discontinuation. A total of 
9 MACEs were positively adjudicated during the study: 4 
Table 3 Additional efficacy outcomes at week 24
  FIL 200 mg+MTX n=416 FIL 100 mg+MTX n=207 FIL 200 mg n=210 MTX n=416
DAS28(CRP) change from baseline
  N 374 190 183 368
  Mean±SD −3.2±1.3 −2.9±1.3 −3.0±1.2 −2.5±1.3
  LSM difference versus MTX (95% CI) −0.8 (−0.9 to –0.6) −0.5 (−0.7 to –0.3) −0.5 (−0.7 to –0.3)
  Exploratory P versus MTX <0.001 <0.001 <0.001
CDAI change from baseline
  N 372 187 184 364
  Mean±SD −31.3±13.2 −30.0±13.3 −31.3±12.6 −28.2±13.4






  Exploratory P versus MTX <0.001 <0.001 <0.001
SDAI change from baseline
  N 372 187 183 362
  Mean±SD −32.7±13.8 −31.1±14.1 −32.7±13.1 −29.0±14.1






  Exploratory P versus MTX <0.001 <0.001 <0.001
SJC66 change from baseline
  N 374 190 186 370
  Mean±SD −14±8.9 −14±8.8 −15±9.5 −13±8.8
  LSM difference versus MTX (95% CI) −2 (−2 to –1) −2 (−2 to –1) −2 (−3 to –1)
  Exploratory P versus MTX <0.001 <0.001 <0.001
TJC68 change from baseline
  N 374 190 186 370
  Mean±SD −20±12.5 −20±13.0 −22±12.4 −19±12.9
  LSM difference versus MTX (95% CI) −2 (−3 to –1) −2 (−3 to –1) −3 (−4 to –1)
  Exploratory P versus MTX <0.001 0.005 <0.001
Patient global assessment change from baseline
  N 374 190 184 370
  Mean±SD −42±26.8 −36±27.4 −38±26.6 −34±27.4
  LSM difference versus MTX (95% CI) −9 (−13 to –6) −3 (−7 to 1) −4 (−8 to 0)
  Exploratory P versus MTX <0.001 0.11 0.066
Physician global assessment change from baseline
  N 372 187 185 364
  Mean±SD −51±21.1 −51±22.2 −49±19.5 −46±21.4
  LSM difference versus MTX (95% CI) −5 (−8 to –3) −4 (−7 to –1) −3 (−6 to 0)
  Exploratory P versus MTX <0.001 0.007 0.046
Patient pain change from baseline
  N 372 190 185 370
  Mean±SD −41±28.0 −37±27.8 −39±26.1 −34±27.6
  LSM difference versus MTX (95% CI) −9 (−12 to –5) −3 (−7 to 1) −4 (−8 to 0)
  Exploratory P versus MTX <0.001 0.13 0.047
hsCRP change from baseline
  N 374 190 186 368
  Mean±SD −13.4±27.1 −10.9±24.5 −12.7±24.5 −7.5±23.5






  Exploratory P versus MTX <0.001 0.007 <0.001
CDAI, Clinical Disease Activity Index; CRP, C- reactive protein; DAS28(CRP), Disease Activity Score in 28 joints with CRP; FIL, filgotinib; hsCRP, high- sensitivity CRP; LSM, least- squares mean; MTX, methotrexate; SDAI, 
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(1%) in FIL200+MTX, 1 (1%) in FIL100+MTX, 2 (1%) in 
FIL200, and 2 (1%) in MTX (table 4). All positively adjudicated 
MACE occurred in patients with cardiovascular risk factors. No 
venous thromboembolism (VTE) occurred with filgotinib; two 
positively adjudicated VTEs (pulmonary emboli) occurred with 
MTX treatment.
Malignancies, excluding non- melanoma skin cancer (NMSC) 
occurred in 4 (1%) patients receiving MTX (breast cancer, 
Table 4 Treatment- emergent adverse events and laboratory abnormalities up to week 52
  FIL 200 mg+MTX n=416 FIL 100 mg+MTX n=207 FIL 200 mg n=210 MTX n=416
Safety summary
TEAE 318 (76%) 164 (79%) 143 (68%) 305 (73%)
TE SAEs 26 (6%) 13 (6%) 17 (8%) 28 (7%)
TEAE leading to premature discontinuation of study drug 28 (7%) 13 (6%) 5 (2%) 25 (6%)
Death 3 (1%) 1 (1%) 0 0
TEAEs in >5% of patients
  Nausea 43 (10%) 32 (16%) 13 (6%) 45 (11%)
  Nasopharyngitis 16 (4%) 13 (6%) 12 (6%) 16 (4%)
  Upper respiratory tract infection 21 (5%) 5 (2%) 9 (4%) 17 (4%)
  Headache 18 (4%) 8 (4%) 5 (2%) 19 (5%)
  Alopaecia 15 (4%) 13 (6%) 3 (1%) 15 (4%)
  Diarrhoea 12 (3%) 10 (5%) 4 (2%) 20 (5%)
TEAEs of special interest
Infection 148 (36%) 76 (37%) 75 (36%) 157 (38%)
Serious infection 5 (1%) 3 (1%) 5 (2%) 8 (2%)
Opportunistic infection 1 (<1%)* 0 0 2 (1%)†
Herpes zoster 6 (1%) 3 (1%) 4 (2%) 4 (1%)
Active TB 0 0 0 0
Malignancy (excluding NMSC) 1 (<1%)‡ 0 0 4 (1%)§
NMSC 2 (1%)¶ 0 0 1 (<1%)**
Gastrointestinal perforations 1 (<1%)†† 0 0 0
Adjudicated VTE 0 0 0 2 (1%)‡‡
Adjudicated MACE 4 (1%)§§ 1 (1%)¶¶ 2 (1%)*** 2 (1%)†††
Laboratory assessments
Haemoglobin change from baseline, mean±SD, g/dL 0.2±1.2 0±1.1 0.4±1.1 −0.1±1.0
  G3 or G4 decrease 6 (2%) 0 1 (1%) 5 (1%)
Neutrophils change from baseline, mean±SD, 103/µL −1.3±2.1 −1.3±2.1 −1.0±2.0 −0.8±1.8
  G3 or G4 decrease 2 (1%) 5 (3%) 2 (1%) 1 (<1%)
Lymphocytes change from baseline, mean±SD, 103/µL −0.2±0.6 −0.2±0.7 −0.1±0.7 −0.1±0.6
  G3 or G4 decrease 14 (3%) 3 (2%) 0 6 (2%)
Platelets change from baseline, mean±SD, 103/µL −40±72.6 −33±66.9 −50±79.6 −18±78.2
  G3 or G4 decrease 1 (<1%) 2 (1%) 0 1 (<1%)
ALT change from baseline, mean±SD, 103/µL 12±29.9 6±22.2 2±13.0 6±19.7
  G3 or G4 increase 18 (4%) 7 (3%) 1 (1%) 4 (1%)
AST change from baseline, mean±SD, 103/µL 9±20.3 7±18.4 5±9.1 4±12.5
  G3 or G4 increase 5 (1%) 3 (2%) 2 (1%) 1 (<1%)
Creatinine change from baseline, mean±SD, 103/µL 0.1±0.1 0.04±0.1 0.1±0.2 0.03±0.1
  G3 or G4 increase 0 0 0 1 (<1%)
CK change from baseline, mean±SD, 103/µL 70±395.1 45±79.3 73±97.2 12±59.7
  G3 or G4 increase 7 (2%) 3 (2%) 3 (1%) 2 (1%)
Fasting LDL cholesterol, change from baseline, mean±SD, mg/dL 17±27.6 12±27.8 14±28.7 2±24.4
  % change, mean±SD 22±32.1 16±29.6 20±33.5 12±23.0
Fasting HDL cholesterol, change from baseline, mean±SD, mg/dL 11±14.5 6±13.6 12±15.3 1±11.0
  % change, mean±SD 21±30.9 12±25.0 21±27.9 6±23.2
Fasting LDL/HDL ratio, mg/dL, change from baseline, mean±SD, mg/dL −0.01±0.63 0.05±0.62 −0.1±0.75 0.001±0.54
Data are shown as n, (%) unless otherwise indicated.
*Oesophageal candida.
†Pneumocystis jirovecii pneumonia and cryptococcal pneumonia.
‡Breast cancer.




‡‡Two adjudicated events of pulmonary embolism.
§§Two adjudicated events of non- fatal stroke, one adjudicated event each of non- fatal MI and CV death (lupus myocarditis).
¶¶Adjudicated CV death (intracranial aneurysm).
***Adjudicated non- fatal MI and non- fatal stroke.
†††Two adjudicated events of non- fatal stroke.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; CV, cardiovascular; FIL, filgotinib; G2, grade 2; G3, grade 3; G4, grade 4; HDL, high- density lipoprotein; LDL, 
low- density lipoprotein; MACE, major adverse cardiovascular event; MI, myocardial infarction; MTX, methotrexate; NMSC, non- melanoma skin cancer; SAE, serious AE; TB, tuberculosis; TE, treatment- emergent; TEAE, 
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malignant melanoma, prostate cancer, and small cell lung 
cancer) and 1 (<1%) receiving FIL200+MTX (breast cancer). 
NMSC occurred in 2 (1%) patients receiving FIL200+MTX and 
1 (<1%) receiving MTX. Diverticular gastrointestinal perfora-
tion occurred in 1 (<1%) patient receiving FIL200+MTX, non- 
steroidal anti- inflammatory drugs, and corticosteroids.
Laboratory abnormalities and TEAEs through 52 weeks are 
presented in table 4.
Mean haemoglobin increased slightly from baseline at week 
52 with filgotinib (online supplemental figure S3). Mean 
decreases in platelets, neutrophils, and lymphocytes remained 
within normal range through week 52 for all treatments. There 
were no grade ≥3 increases in platelets. There was no temporal 
association between low lymphocytes and infection.
Grade 3 liver enzyme elevations were more frequent versus 
MTX with FIL200+MTX and FIL100+MTX, but comparable 
for FIL200 and MTX (table 4). However, no case satisfied Hy’s 
law to suggest drug- induced hepatocellular injury. Grade 3 
creatinine increase was reported with MTX; none occurred with 
filgotinib. Grade 3 creatine kinase (CK) elevation incidence was 
similar with filgotinib versus MTX; grade 4 elevation occurred 
only with filgotinib. These events were transient, without symp-
toms of muscle toxicity or rhabdomyolysis. One patient receiving 
FIL200 discontinued due to asymptomatic grade 3 CK elevation. 
Cholesterols increased by a mean (SD) of 17 (28), 12 (28), and 
14 (29) mg/dL for low- density lipoprotein (LDL) cholesterol and 
11 (15), 6 (14), and 12 (15) mg/dL for high- density lipoprotein 
(HDL) cholesterol with FIL200+MTX, FIL100+MTX, and 
FIL200, respectively; however, LDL/HDL ratios remained stable 
(table 4).
DISCUSSION
Early diagnosis and treatment are desirable to achieve RA 
treatment goals: induction of remission, maintenance of phys-
ical function, and maximisation of patient QoL.2 6 Although 
treatment with all filgotinib regimens and MTX in the current 
study were effective in improving disease activity, physical func-
tion, and patient reported outcomes, patients who received 
FIL200+MTX or FIL100+MTX achieved a superior ACR20 
response and improvements in HAQ- DI and DAS28(CRP) <2.6 
at week 24 compared with MTX. However, the proportion 
of patients achieving ACR20 at week 24 treated with FIL200 
monotherapy did not attain statistical significance versus MTX 
in the hierarchical testing scheme.
The clinical benefits achieved in the study were considered 
alongside the potential risks of all treatment regimens. Over 
52 weeks, rates of serious AEs, infections, serious infections, 
opportunistic infections, herpes zoster, MACE and malignancies 
were similar between filgotinib and MTX arms. No VTEs were 
observed in patients receiving filgotinib. Three deaths occurred 
in patients receiving filgotinib and an additional death occurred 
more than 2 months after cessation of filgotinib. There was no 
pattern in specific cause of death, and events were consistent 
with common causes of mortality in RA apart from the event of 
lupus myocardiopathy.20
Liver enzyme elevations were more commonly observed with 
filgotinib in combination with MTX than with either filgotinib 
monotherapy or MTX. However, no reported case satisfied 
Hy’s law to suggest drug- induced liver injury. Filgotinib, either 
as a monotherapy or with MTX, was associated with decreases 
in neutrophil, lymphocyte, and platelet counts, and increases 
in lipids and CK. These results were similar to prior filgotinib 
trials.11–13 MTX monotherapy was also associated with decreases 
in neutrophil, lymphocyte, and platelet counts; such decreases 
are an expected feature of successful reduction in RA disease 
activity. The longer term safety of filgotinib is being evaluated in 
two ongoing LTE trials (NCT02065700; NCT03025308).
Limitations of this study include that the design precluded 
adjusting the MTX dose following the initial 8- week period, 
increasing the dose >20 mg/week, or switching to an inject-
able formulation. Additionally, patients receiving concomi-
tant glucocorticoids were required to receive a stable dose, 
precluding use as short- term bridging therapy. The lack of 
a placebo group might have increased the response in all 
treatment groups due to expectation bias. Nevertheless, the 
responses observed with filgotinib are consistent with other 
studies of filgotinib.11–13 The inability to demonstrate superi-
ority of FIL200 monotherapy versus MTX for ACR20 at week 
24 precluded further claims of statistical significance for other 
clinically important endpoints, such as physical function and 
remission, for which FIL200 appeared to have benefit over 
MTX. Finally, the low progression rate of structural damage 
compromised the ability to demonstrate a benefit between 
filgotinib arms versus MTX.
In early RA, separation between two active medications can be 
observed based on the proportion of patients achieving the clin-
ically meaningful threshold such as the ACR20 but also by the 
depth of response seen by those on treatment. Thus, two medi-
cations can show similar proportions of ACR20 responses, and 
their true difference in efficacy is only revealed when assessing 
ACR50 and ACR70 responses.21 Although ACR20 was chosen 
as the primary endpoint, other endpoints of clinical interest 
were also evaluated. All filgotinib treatments achieved numeri-
cally better disease control versus MTX alone for higher hurdle 
endpoints such as ACR50/70 and remission.
Early intensive treatment aims to limit both disease activity—
ideally inducing disease remission—and progression of struc-
tural damage that could lead to loss of function and disability in 
the long term. Despite aiming to enrich the study with patients 
at risk for structural progression, the proportion of patients in 
whom structural damage progressed was low. While longer dura-
tion of follow- up may be necessary to demonstrate the impact 
of filgotinib on irreversible joint damage, overall, there was less 
progression of structural damage with all filgotinib treatments 
versus MTX alone at week 52 and with FIL 200 mg at week 24. 
These comparisons were not adjusted for multiplicity, and thus 
no final conclusion can be drawn.
As current guidelines recommend early initiation of DMARDs 
after RA diagnosis, it is important to note that 34% of the 
patients enrolled in the study had disease duration >1 year with 
no DMARD therapy prior to study enrolment, which may limit 
the generalisability of our findings. However, in sensitivity anal-
yses in which patients were stratified by disease duration of <1 
or>1 year (data not shown), results were similar regardless of 
disease duration for all endpoints evaluated.
In patients with active RA who had limited or no prior MTX 
exposure, filgotinib with MTX reduced signs and symptoms 
of RA and improved physical function, and these effects were 
sustained through 52 weeks. Both filgotinib doses were well 
tolerated with an acceptable safety profile. Given the high- 
hurdle outcomes at week 52, an initial dose of filgotinib 200 
mg eventually tapering to 100 mg in patients with good disease 
control at 1 year may be considered in clinical practice. An addi-
tional study evaluating early, temporary use of JAK- inhibitors or 
bDMARDs in patients with a suboptimal early response to initial 
MTX and tapering glucocorticoids is needed to assess potential 
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